Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-09-09T20:00:01.000Z.
Consensus retrieved: 2026-09-10T03:25:20.705Z. This records retrieval, including cache reads, rather than vendor publication. A quote earlier than this retrieval cannot support current forward valuation.
Quote observation: 2026-09-09T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bef7f289391c7460483e20d6a2b52610481c87f785e36ab51e0e8a2f1a0a8930
FORWARD PE RATIO
N/A
Moderna, Inc.
Market Cap
$53.81B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Moderna, Inc. (MRNA) | $53.81B | N/A |
| Cardinal Health, Inc. (CAH)vs › | $56.21B | N/A |
| Edwards Lifesciences Corporation (EW)vs › | $49.62B | N/A |
| Becton, Dickinson and Company (BDX)vs › | $49.54B | N/A |
| Humana Inc. (HUM)vs › | $48.03B | N/A |
| Cencora, Inc. (COR)vs › | $62.91B | N/A |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.92B | N/A |
| IQVIA Holdings Inc. (IQV)vs › | $42.30B | N/A |
| Agilent Technologies, Inc. (A)vs › | $40.89B | N/A |
| Boston Scientific Corporation (BSX)vs › | $66.83B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $135.61 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-8.33 | $-10.34 – $-7.84 | 16 | n/m |
| 2027-12-31 | $-4.80 | $-7.55 – $-2.90 | 15 | n/m |
| 2028-12-31 | $-2.82 | $-5.58 – $0.63 | 14 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
